CORRIGENDUM

Conditioning the genome identifies additional diabetes resistance loci in Type 1 diabetes-resistant NOR/Lt mice

PC Reifsnyder, R Li, PA Silveira, G Churchill, DV Serreze and EH Leiter

Genes and Immunity (2006) 7, 184. doi:10.1038/sj.gene.6364292

Correction to: Genes and Immunity (2005) 6, 528-538.
 doi: 10.1038/sj.gene.6364241

Since the publication of the above article, the authors have identified an error in Figure 1 and its legend. Owing to a misleading genotyping, *D4Mit310* was originally scored as NOD-derived indicating that the congenic possessed a shorter BKS-derived region than in the parental NOR. Figure 1c has been corrected to show that the congenic bears the full NOR-derived Chromo-

some 4 congenic interval assessed in our study. This spans not only a region containing genes exerting the previously reported *Idd11* and *Idd9.1* locus effects (Refs. 11-13), but also that of the *Idd9.2* locus. Markers are ordered according to Ensembl physical map location (in Mb) rather than MGI linkage map position (in cM).

The correct figure is shown below.
 The authors would like to apologize for this mistake.

Figure 1 Schematic illustrations showing polymorphic markers defining congenic intervals. Genomic marker positions are shown in Mb (Ensembl, Build 33) and cM (MGI, The Jackson Laboratory), with B6 or DBA-derived regions from BKS indicated if known. All markers known to distinguish NOR from NOD in the relevant congenic regions are presented; those actually typed in congenic construction are described in Materials and methods. (a) Comparison of NOR Chr. 2 and the N21 NOR.NOD-*Il1* congenic stock conditioned by replacement of NOR with NOD alleles below *D2Mit277*. (b) Length of NOR congenic interval in the NOD.NOR-Chr. 1 congenic stock. (c) Length of NOR congenic interval in the NOD.NOR-Chr. 4 congenic stock.